Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc.BTX · Entity 6045 | Sr VP, Head of Corporate Dev | October 19, 2016 | December 15, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lineage Cell Therapeutics, Inc.
Report date October 19, 2016 · Filed December 15, 2016 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, no par valueSEC Table I · non-derivative | Direct | 17,704 |
Reported balance
Holding disclosure · report date 2016-10-19 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 17,704 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 19, 2016 Filed Nov 19, 2016 01:58 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 300,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001209191-16-151321 · doc4.xml · derivative · entry 1 KNIGHT JAMES A. · CIK 0001690272 · Sr VP, Head of Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Shares · 300,000 shares Expires 2026-10-18 F1 · derivative.exercise_date: One quarter of the options shall vest on October 18, 2017, subject to the completion of 12 months of continuous employment from the date of grant on October 19, 2016, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.